Abstract Search

ea0089c1 | Clinical – Chemo/SSA/Biologics | NANETS2022

Progression-Free Survival in Patients with Bronchopulmonary Neuroendocrine Tumors Treated with Lanreotide or Placebo: Adjustment for Crossover Effects in Placebo Arm

Singh Simron , Buikhuisen Wieneke , Capdevila Jaume , Caplin Martyn E , Grohe Christian , Horsch Dieter , Raderer Markus , Reidy-Lagunes Diane , Wolin Edward M , Pommie Christelle , Mai Truong Xuan , Baudin Eric

Background: SPINET was a phase 3 trial (NCT02683941) in patients with well-differentiated, advanced bronchopulmonary neuroendocrine tumors (NETs; typical and atypical carcinoids [TCs and ACs]). During the double-blind (DB) period, patients were randomized (2:1) to receive lanreotide autogel/depot (LAN; 120 mg) or placebo (PBO) every 28 days; in the optional open-label (OL) phase, all patients received LAN. Recruitment was stopped early due to slow accrual; all eligible patient...

0 shares

Endocrine Abstracts

Progression-Free Survival in Patients with Bronchopulmonary Neuroendocrine Tumors Treated with Lanreotide or Placebo: Adjustment for Crossover Effects in Placebo Arm

BiosciAbstracts